Literature DB >> 9334883

Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs.

A Takahara1, H Dohmoto, H Hisa, S Satoh, R Yoshimoto.   

Abstract

We examined the effects of cilnidipine, which is an L- and N-type Ca2+ channel blocker, on adrenergically regulated renal functions in anesthetized dogs. Renal nerve stimulation (RNS) at high frequency (3-7 Hz) decreased renal blood flow (RBF) without changes in systemic blood pressure. The RBF response was inhibited by intrarenal arterial (i.r.a.) infusion of cilnidipine at 0.1-0.3 microgram/kg/min. Low-frequency RNS (0.5-1 Hz) reduced absolute and fractional urinary sodium excretion. These responses were attenuated during i.r.a. infusion of cilnidipine at 0.3 microgram/kg/min. An increase in norepinephrine secretion rate induced by low-frequency RNS was also attenuated during cilnidipine infusion. These results suggest that cilnidipine can suppress norepinephrine release from the renal nerve endings and thereby interfere with the neural control of renal functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334883     DOI: 10.1254/jjp.75.27

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  8 in total

1.  L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.

Authors:  Shizuka Aritomi; Tomoyuki Konda; Michihiro Yoshimura
Journal:  Heart Vessels       Date:  2011-10-12       Impact factor: 2.037

2.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Authors:  Shizuka Aritomi; Kazumi Niinuma; Tetsuya Ogawa; Tomoyuki Konda; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-17       Impact factor: 2.801

3.  Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

Authors:  A Takahara; Y Nakamura; H Wagatsuma; S Aritomi; A Nakayama; Y Satoh; Y Akie; A Sugiyama
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

4.  Oral administration of cilnidipine to patients with hypertensive intracerebral hemorrhage in the acute stage: significance and role of an N-type calcium channel blocker.

Authors:  A Matsuno; F Ide; H Tanaka; S Asano; S Miyawaki; T Uno; J Tanaka; H Nakaguchi; M Sasaki; M Murakami; N Fuke
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 1.568

5.  N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Authors:  Bai Lei; Daisuke Nakano; Yoshihide Fujisawa; Ya Liu; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Katsuhiko Asanuma; Yasuhiko Tomino; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2012-07-21       Impact factor: 3.337

Review 6.  Calcium channel blocker in patients with chronic kidney disease.

Authors:  Shoko Ohno; Akira Ishii; Motoko Yanagita; Hideki Yokoi
Journal:  Clin Exp Nephrol       Date:  2021-11-08       Impact factor: 2.801

7.  A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities.

Authors:  Rugmani Padmanabhan Iyer; Merry L Lindsey; Robert J Chilton
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

8.  On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.

Authors:  Tadashi Konoshita; Saori Kaeriyama; Machi Urabe; Takahiro Nakaya; Mika Yamada; Mai Ichikawa; Katsushi Yamamoto; Satsuki Sato; Michiko Imagawa; Miki Fujii; Yasukazu Makino; Yasuo Zenimaru; Shigeyuki Wakahara; Jinya Suzuki; Tamotsu Ishizuka; Hiroyuki Nakamura
Journal:  Biosci Rep       Date:  2016-09-16       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.